(redirected from Jetrea)


(ok-plas-min) ,


(trade name)


Therapeutic: ocular agents
Pharmacologic: enzymes
Pregnancy Category: C


Symptomatic treatment of vitreomacular adhesion (VMA).


A proteolytic enzyme that dissolves the protein matrix present in vitreomacular adhesions.

Therapeutic effects

Dissolution of vitreomacular adhesion with improved vision.


Absorption: Minimal absorption
Distribution: Action is primarily local
Metabolism and Excretion: Rapidly degraded following administration
Half-life: Unknown.

Time/action profile (VMA resolution)

Intravitrealwithin 1 wk3 wk6 mos or more


Contraindicated in: None noted.
Use Cautiously in: Lactation: Effects are not know, use caution Obstetric: Use during pregnancy only if clearly needed Pediatric: Safe and effective use in children has not been established

Adverse Reactions/Side Effects

May be due to procedure

Ear, Eye, Nose, Throat

  • blurred vision (most frequent)
  • conjunctival hemorrhage (most frequent)
  • ↓ visual acuity (most frequent)
  • eye pain (most frequent)
  • macular hole (most frequent)
  • vitreous floaters (most frequent)
  • retinal edema (most frequent)
  • anterior chamber cell
  • cataract
  • conjunctival hyperemia
  • dry eye
  • dyschromatopsia (yellow vision)
  • ↑ intraocular pressure
  • intraocular inflammation/infection
  • intraocular hemorrhage
  • iritis
  • lens subluxation
  • macular edema
  • metamorphopsia (distorted vision)
  • photophobia
  • photopsia (perceived light flashes)
  • retinal degeneration
  • retinal detachment
  • vitreous detachment


Drug-Drug interaction

None noted.


Intravitreal (Adults) 0.125 mg injected as a single dose


Solution for intravitreal injection: 0.5 mg/0.2 mL

Nursing implications

Nursing assessment

  • Monitor for elevation in intraocular pressure following injection.
  • Monitor visual acuity periodically following injection; may lead to decrease in vision.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Ocriplasmin must be administered by a qualified physician.
  • Intravitreal: Remove vial from freezer and allow to thaw for few min at room temperature. Add 0.2 mL of preservative free 0.9% NaCl. Swirl gently until mixed. Solution is clear and colorless without particles; do not administer solutions that are discolored or contain particulate matter. Withdraw all solution from vial with a 19 gauge needle. Replace needle with 30 gauge needle and expel excess air and solution to 0.1 mL. Discard unused solution. Administer adequate anesthesia and a broad spectrum antibiotic as per protocol. Intravitreal injection is done via aseptic technique. Repeat administration in same eye is not recommended.
    • Wait 7 days before treating other eye if necessary.

Patient/Family Teaching

  • Explain procedure for intravitreal injection to patient.
  • Advise patient to notify health care professional immediately if signs and symptoms of intraocular inflammation/infection (eye redness, sensitivity to light, eye pain, change in vision) occurs.
  • May cause visual changes. Advise patient to avoid driving and other activities requiring good vision until response to medication is known.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Improved vision in patients with vitreomacular adhesions.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
He has been involved with the development and approval of four drugs, Jetrea being the latest one.
It also owns the global rights to JETREA (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (outside the US).
For example, ThromboGenics initiated partnership with Novartis (Alcon) for assisting in commercialization and marketing activities of JETREA beyond the U.S.
No human eye data were found for ocriplasmin (Jetrea), an agent given as an intravitreal injection.
April 23 (SeeNews) - Belgian biopharmaceutical firmA ThromboGenicsA NV (EBR:THR) said Thursday it is evaluating its eye drug Jetrea as a potential treatment for retinal vein occlusion (RVO), which is the product's third indication.
MISSISSAUGA, Ontario -- Alcon, the eye care division of Novartis, has received Health Canada's approval of Jetrea solution for injection for treating symptomatic vitreomacular adhesion (VMA) an age-related, progressive sight-threatening condition that, if left untreated, can be responsible for retinal distortion, decreased visual acuity and vision deterioration.
As CCO at ThromboGenics, Vangeersdaele will lead and develop the overall commercial strategy for the company's recently formed global JETREA business unit, which was created after ThromboGenics regained the full global rights to JETREA from Novartis.
A novel nonsurgical intervention for VMT is intravitreal injection of ocriplasmin (trade name Jetrea) [4].
Previously, the only treatment option available for this patient would have been vitrectomy However, advances in pharmaceuticals have led to the development of ocriplasmin (Jetrea), an intravitreal injection containing protease enzyme, which breaks down the vitreoretinal attachments, inducing PVD.